Skip to main content
Back
RGC logo

Regencell Bioscience Holdings Limited

Data quality: 100%
RGC
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$25.22
▼ $2.16 (-7.87%)
Mkt Cap: 12.47B
Day Range
$24.86 $27.02
52-Week Range
$0.55 $83.60
Volume
112,793
50D / 200D Avg
$28.38 / $20.03
Prev Close
$27.37

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -3478.7 0.4
P/B 2565.4 2.9
ROE % -54.8 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.1 0.2

Key Takeaways

Debt/Equity of 0.11 — conservative balance sheet
Negative free cash flow of -3.27M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-54.81%
ROIC-52.32%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.11
Current Ratio7.39
Interest Coverage0.00

Valuation

P/E Ratio
-3478.74
P/B Ratio2565.40
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -3.58M
ROE -54.81% ROA -62.27%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3.27M
ROIC -52.32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.11 Current Ratio 7.39
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -3478.74 P/B Ratio 2565.40
P/S Ratio N/A PEG Ratio 136.35
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 12.47B Enterprise Value 12.47B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -3.58M -4.30M -5.87M -7.42M -1.35M
EPS (Diluted) -0.01 -0.01 -0.01 -0.02 0.00
Gross Profit -392,743.0 -745,588.0 -769,687.0 -604,397.0 -26,456.0
Operating Income -3.77M -4.74M -6.27M -7.62M -1.38M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.76M 8.44M 12.62M 18.02M 340,134.0
Total Liabilities 895,308.0 219,512.0 632,320.0 938,032.0 4.34M
Shareholders' Equity 4.86M 8.22M 12.03M 17.07M -4.00M
Total Debt 544,415.0 85,741.0 463,669.0 771,255.0 3.68M
Cash & Equivalents 2.42M 2.96M 1.56M 6.42M 59,413.0
Current Assets 4.90M 8.11M 11.62M 16.44M 66,849.0
Current Liabilities 663,673.0 193,578.0 606,914.0 577,764.0 4.34M